Novo Nordisk CFO outlines ‘ultimate defense’ against stock downgrades and lawsuits to retain weight-loss crown

The ultimate defense in our industry is in innovation,” Karsten Munk Knudsen told Fortune in an exclusive interview.

Novo Nordisk: Problems Compound, But Stock Still Cheap (Rating Downgrade)

Novo Nordisk A/S downgraded after Q3 earnings and weight loss sector risks. Explore valuation, partnerships, and market outlook. Read why NVO stock is a Buy.

Is Novo Nordisk (NVO) The Best Weight-Loss Stock to Buy?

Karen Finerman, CEO & Co-founder, Metropolitan Capital Advisors, said in a recent program on CNBC that she likes NVO amid the company’s weight-loss drug business. “All this talk about GLP-1s? No, I’m not going toward Lilly, which I do own, but I am also going toward Novo Nordisk A/S (NYSE:NVO).”

Higher-Dose Of Wegovy Demonstrates Weight Loss And Cardiovascular Benefits

Novo Nordisk reports Wegovy users lost 21% body weight and saw improved heart health markers, as EMA and FDA reviews near for new doses.

Novo Nordisk's experimental obesity drug CagriSema shows blood pressure benefits

Novo Nordisk said on Thursday its experimental obesity drug CagriSema significantly reduced blood pressure in a late-stage trial, as the Danish drugmaker seeks to demonstrate health benefits beyond weight loss for a treatment that has disappointed investors.

Increased access to weight loss drugs can lower health care costs down the line, doctor says

President Trump announced a deal with Eli Lilly and Novo Nordisk on Thursday to lower the cost of their weight loss drugs for some Americans. Dr. Holly Lofton, NYU Langone Medical's weight management program director,
Feedback